跳至主要内容
临床试验/NCT04042974
NCT04042974Unknown4 期

Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients:a Randomized Controlled Trial

Cairo University0 个研究点目标入组 100 人开始时间: 2019年8月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
100
主要终点
Intensity of pain

研究概览

简要总结

To compare the effectiveness of vaginal dinoprostone with placebo in minimizing the pain experienced by primarily infertile patients during diagnostic office hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopist.

详细描述

hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as polyps, fibroids, septa, and adhesions, and in the presence of abnormal bleeding and during the removal of an intrauterine device or foreign body. Cervical ripening is made possible by the use of medication through different routes. The most commonly used agent is misoprostol, a synthetic prostaglandin E1 (PGE1) analog that is frequently administered in off-label use in obstetrics and gynecology for medical abortion, labor induction, endometrial biopsy, dilatation and curettage, intrauterine device insertion, myomectomy, postpartum haemorrhage, and cervical ripening. In contrast, dinoprostone, a natural PGE2, is mostly used in obstetrics for cervical ripening and the stimulation of uterine contractions to induce labor.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
15 Years 至 40 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • nulliparous women with primary infertility requiring a diagnostic hysteroscopy as a part of an infertility diagnosis workup

排除标准

  • • women with suspected pregnancy
  • heavy vaginal bleeding
  • recent pelvic infection
  • those known to have hypersensitivity or contraindication to dinoprostone
  • those who received analgesics prior to OH
  • a concomitant neurologic disease that could affect the correct evaluation of pain

研究组 & 干预措施

dinoprostone

Experimental

1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.

干预措施: vaginal dinoprostone (Drug)

placebo

Placebo Comparator

one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.

干预措施: placebo (Drug)

结局指标

主要结局

Intensity of pain

时间窗: an expected average of 10 minutes

Pain intensity will be assessed by visual analogue scale during the procedure.visual analogue scale ranging from 0 to 10

次要结局

  • Operative time(an expected average 10 minutes)
  • Intensity of pain(30 minutes after the procedure)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Samy aly ashour

assistant professor

Cairo University

相似试验

Vaginal Dinoprostone Prior to Diagnostic Office... | 临床试验